Results 41 to 50 of about 129,296 (209)

The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. [PDF]

PLoS ONE, 2013
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC ...
Olivier Peulen, Arnaud Gonzalez, Paul Peixoto, Andrei Turtoi, Denis Mottet, Philippe Delvenne, Vincent Castronovo   +6 more
doaj   +1 more source

Mass-Forming Chronic Pancreatitis: Diagnostic Performance of PET/CT

World Journal of Nuclear Medicine, 2022
Mass-forming chronic pancreatitis and pancreatic ductal adenocarcinoma are most commonly located in the head of pancreas, and there is a marked overlap in clinical features and imaging findings that makes it diagnostically challenging, although prognosis
Ravikanth Reddy
doaj   +1 more source

ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer death; identifying PDAC enablers may reveal potential therapeutic targets. Expression of the actomyosin regulatory ROCK1 and ROCK2 kinases increased with tumor progression in human and ...
Anderson, Kurt I., Helbig, Lena, Julian, Linda, Kadir, Shereen, Kalna, Gabriela, McGhee, Ewan J., Morton, Jennifer P., Mullin, Margaret, Olson, Michael F., Pinho, Andreia V., Rath, Nicola, Rooman, Ilse, Samuel, Michael S.   +12 more
core   +1 more source

The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression

Nature Communications, 2022
The advent of immunotherapy has revolutionised cancer therapeutics, but its application in the context of pancreatic ductal adenocarcinoma has been limited.
Anne E. Geller, Rejeena Shrestha, Matthew R. Woeste, Haixun Guo, Xiaoling Hu, Chuanlin Ding, Kalina Andreeva, Julia H. Chariker, Mingqian Zhou, David Tieri, Corey T. Watson, Robert A. Mitchell, Huang-ge Zhang, Yan Li, Robert C. G. Martin II, Eric C. Rouchka, Jun Yan   +16 more
doaj   +1 more source

Pancreatic ductal adenocarcinoma [PDF]

, 2013
A 61-year-old gentleman who lives with his wife and 20-year-old son, presented to the polyclinic with a four week history of pruritus. On examination he was found to be jaundiced and his LFTs were high.
Bezzina, Sarah, Debattista, Daniel
core  

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. [PDF]

, 2018
BACKGROUND: Variation in an individual\u27s genetic status can impact the development of pancreatic ductal adenocarcinoma; however, the majority of familial pancreatic cancers (FPC) cannot yet be attributed to a specific inherited mutation.
Brody, Jonathan, Cozzitorto, Joseph A., Goetz, Austin, Lavu, Harish, Muller, Alexander J., Nevler, Avinoam, Prendergast, George C., Winter, Jordan M., Yeo, Charles, Yeo, Theresa P.   +9 more
core   +2 more sources

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]

, 2018
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali, Del Vecchio, Annachiara, Espinoza, Carlos, Fabo, Tania, Fearon, Eric R., Feng, Ying, Galbán, Stefanie, Halbrook, Christopher J., Karim, Saadia A., Kovalenko, Ilya, Kremer, Daniel M., Kumar-Sinha, Chandan, Lee, Ho-Joon, Ljungman, Mats, Lyssiotis, Costas A., Magnuson, Brian, Morton, Jennifer P., Pasca di Magliano, Marina, Schofield, Heather K., Yan, Wei, Zeller, Jörg   +20 more
core   +1 more source

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer [PDF]

, 2017
Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of ~8%, restricted treatment options and characteristic molecular heterogeneity.
A H Allam, A Neesse, A Neesse, A V Biankin, A Xue, AB Seymour, AD Rhim, AK Witkiewicz, AM LeBeau, AR Shekouh, AV Biankin, B Hinz, BC Ozdemir, BJ Cochran, BJ Cochran, C Gaggioli, C Vennin, D Croucher, D Goldstein, D Herrmann, D Herrmann, D Mahadevan, D N Saunders, D Telgenhoff, DD Von Hoff, DR Croucher, DR Croucher, E Cerami, F Al-Ejeh, G Finak, H Shiomi, HW Smith, I Garrido-Laguna, J Condeelis, J Gao, J Gore, J Lee, J Li, J P Morton, J R W Conway, JA Lee, JJ Lee, JP Morton, K Kessenbrock, K L Vine, L Harris, M C Lucas, M J Cowley, M Nobis, M Pajic, M Pinese, M Ranson, MJ Duffy, ML Nyström, N L E Harris, N Waddell, P Bailey, P Carmeliet, P Timpson, P Timpson, R Cicchi, R F Shearer, R Kalluri, R Smith, RF Shearer, RG Rowe, RL Siegel, S Nurmenniemi, S Ulisse, SC Barry, SR Hingorani, SR Hingorani, TK Stutchbury, WA Schroder, Y Takeuchi, ZS Boyd, Ö Babur   +76 more
core   +1 more source

Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. [PDF]

PLoS ONE, 2017
Pancreatic ductal adenocarcinoma, which accounts for the majority of pancreatic cancers, is a lethal disease with few therapeutic options. Genomic profiling of pancreatic ductal adenocarcinoma has identified a complex and heterogeneous landscape ...
Jeran K Stratford, Feng Yan, Rebecca A Hill, Michael B Major, Lee M Graves, Channing J Der, Jen Jen Yeh   +6 more
doaj   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source